权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Innovative Translational Imaging Technologies to Monitor Genome Edited Cells in Vivo

用于监测体内基因组编辑细胞的创新转化成像技术

基本信息

批准号：
10017228
负责人：
DAVID J SEGAL
金额：
$ 22.79万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-15 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10017228
关键词：
Address Animal Model Biological Assay Cell Count Cells Clinical Clinical Trials Detection Development Functional disorder Future Genes Goals Human Image Imaging technology Immune response In Vitro Infrastructure Investigation Knowledge Label Liver Low Dose Radiation Measures Methodology Methods Modeling Monitor Muscle Outcome Phase Polymers Population Positron-Emission Tomography Proteins Protocols documentation Radiation Dose Unit Reporter Reproducibility of Results Research Personnel Resources Risk Safety Shapes Signal Transduction Site System Technology Testing Time Tissues Translations Work age group base body system cell type clinical investigation design gene product genome editing human disease human imaging imaging system in vivo in vivo evaluation in vivo imaging innovation intein meetings multidisciplinary new technology non-invasive imaging preclinical study prototype quantitative imaging response safety assessment scaffold simulation somatic cell gene editing success temporal measurement tool vector

项目摘要

PROJECT SUMMARY / ABSTRACT This application is submitted in response to RFA-RM-18-025, which is focused on the development of new technologies to noninvasively label and monitor genome-edited cells in vivo. Our submission meets the objective of the RFA by establishing a new field of total-body positron emission tomography (PET) imaging for somatic cell genome editing, and with quantitative methodologies needed to support translation. This application is grounded in a proven infrastructure of innovative tools, technologies, and resources, and a highly accomplished multidisciplinary team of investigators. Studies will culminate in translational tools for the in vitro design (phantoms, quantitative measures) and in vivo methods for monitoring genome-edited cells that will inform future clinical investigations across organ systems for the treatment of human disease. The UH2 phase will focus on in vitro and in vivo quantitative testing with edited cells in prototype models (Specific Aim 1). The activities in these studies can be adapted to any cell type or organ system. The UH3 phase will address detection efficiency and safety assessments in vivo, including the potential for immune responses in an animal model that employs quantitative imaging analysis and related tools for translation (Specific Aim 2). Overall, these investigations will establish a new field of total-body PET imaging for monitoring the safety and efficiency of somatic cell genome editing and will contribute new knowledge that leads to future well-designed preclinical studies and human clinical trials.

项目概要/摘要本申请是为了响应 RFA-RM-18-025 而提交的，该申请的重点是开发新的非侵入性标记和监测体内基因组编辑细胞的技术。我们的提交符合 RFA 的目标是建立全身正电子发射断层扫描 (PET) 成像的新领域体细胞基因组编辑，以及支持翻译所需的定量方法。这应用程序基于经过验证的创新工具、技术和资源基础设施，以及高度成就卓著的多学科研究团队。研究将最终产生体外转化工具用于监测基因组编辑细胞的设计（模型、定量测量）和体内方法为未来治疗人类疾病的跨器官系统的临床研究提供信息。 UH2相将重点关注原型模型中经过编辑的细胞的体外和体内定量测试（具体目标 1）。这这些研究中的活动可以适应任何细胞类型或器官系统。 UH3阶段将解决体内检测效率和安全性评估，包括动物免疫反应的潜力采用定量成像分析和相关翻译工具的模型（具体目标 2）。全面的，这些研究将建立全身 PET 成像的新领域，用于监测安全性和效率体细胞基因组编辑，并将贡献新知识，为未来精心设计的临床前研究和人体临床试验。